Felipe Salech Selected Research

Alzheimer Disease (Alzheimer's Disease)

1/2020	Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease.
1/2018	Cancer Imprints an Increased PARP-1 and p53-Dependent Resistance to Oxidative Stress on Lymphocytes of Patients That Later Develop Alzheimer's Disease.
1/2017	PARP-1 and p53 Regulate the Increased Susceptibility to Oxidative Death of Lymphocytes from MCI and AD Patients.
1/2014	Increased susceptibility to oxidative death of lymphocytes from Alzheimer patients correlates with dementia severity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Felipe Salech Research Topics

Disease

4	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2014
2	Neoplasms (Cancer) 01/2020 - 01/2018
2	Skin Neoplasms (Skin Cancer) 01/2018 - 01/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Cognitive Dysfunction 01/2018
1	Dementia (Dementias) 01/2017
1	Necrosis 07/2011
1	Disease Progression 01/2011
1	Epithelioid Hemangioendothelioma 01/2011
1	Tuberculous Peritonitis 09/2006
1	Tuberculosis (Tuberculoses) 09/2006

Drug/Important Bio-Agent (IBA)

3	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2018 - 01/2014
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2020 - 07/2011
1	LigandsIBA 01/2020
1	A-Form DNA (A-DNA)IBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	Niacinamide (Nicotinamide)FDA LinkGeneric 01/2020
1	EnzymesIBA 01/2020
1	Biological ProductsIBA 01/2018
1	Vitamin D FDA LinkGeneric 01/2018
1	CaspasesIBA 07/2011
1	Pharmaceutical PreparationsIBA 01/2011
1	Thalidomide (Thalomid)FDA Link 01/2011
1	Adenosine DeaminaseIBA 09/2006

Therapy/Procedure

2	Therapeutics 01/2020 - 01/2011
1	Aftercare (After-Treatment) 01/2011